Frontier Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Frontier Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$21K	Sell	10,500 -10,000	-49%	-$17.3K	﹤0.01%	388
2022 Q1	$41K	Buy	+20,500	New	+$63.9K	﹤0.01%	395

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Frontier Wealth Management's SRNE Position: Q2 2022 in Review

Frontier Wealth Management reduced its Sorrento Therapeutics, Inc. (SRNE) stake by 49% in Q2 2022, selling an estimated $17.3K and leaving 10,500 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

Frontier Wealth Management first reported a position in SRNE in Q1 2022 and has held it in 2 quarters since. The position peaked at $41K in Q1 2022. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

Frontier Wealth Management held 10,500 shares of Sorrento Therapeutics, Inc. worth $21K as of Q2 2022.
Frontier Wealth Management sold 10,000 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $17.3K.
Sorrento Therapeutics, Inc. made up ﹤0.01% of Frontier Wealth Management's portfolio in Q2 2022, its #388 holding.
Frontier Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2022 and has held it in 2 quarters since.
Frontier Wealth Management's Sorrento Therapeutics, Inc. position peaked at $41K in Q1 2022.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.